Windlas Biotech's Q4 FY 2025-26 Quarterly Results

Result Summary

• Windlas Biotech Ltd reported a 2.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 17.0%.
• Its expenses for the quarter were up by 2.3% QoQ and 19.2% YoY.
• The net profit increased 6.6% QoQ and decreased 1.8% YoY.
• The earnings per share (EPS) of Windlas Biotech Ltd stood at 7.49 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Windlas Biotech Ltd is a company engaged in the pharmaceutical industry, focusing on providing contract development and manufacturing services. The company is involved in the production of generic pharmaceutical products, offering end-to-end solutions covering product development, manufacturing, and packaging. Known for its expertise in the formulation of solid dosage products, Windlas Biotech Ltd has established itself as a significant player in its sector. Recent major developments in the company, such as specific product launches or strategic partnerships, are not available from the provided data.

Revenue

For the quarter ending Q4FY26, Windlas Biotech Ltd reported a total income of ₹242.85 crores, showing a quarter-over-quarter (QoQ) increase of 2.2% from ₹237.67 crores in Q3FY26. On a year-over-year (YoY) basis, the total income rose by 17.0% compared to ₹207.64 crores in Q4FY25. This growth in total income suggests an upward trend in revenue generation over the past year. The consistent increase in income over successive quarters indicates a sustained ability to generate revenue, contributing to the company's financial health.

Profitability

Windlas Biotech Ltd's profitability metrics for Q4FY26 indicate a Profit Before Tax (PBT) of ₹20.16 crores, reflecting a slight QoQ increase of 1.0% from ₹19.97 crores in Q3FY26. However, there is a YoY decrease of 3.2% from the PBT of ₹20.82 crores in Q4FY25. The Profit After Tax (PAT) for Q4FY26 stands at ₹15.99 crores, showing a QoQ increase of 6.6% from ₹15.00 crores in Q3FY26 but a YoY decrease of 1.8% from ₹16.28 crores in Q4FY25. Earnings Per Share (EPS) were ₹7.49 in Q4FY26, which is a 6.2% increase QoQ and a 2.6% decrease YoY. These metrics suggest varied performance in profitability over the quarters, with notable changes in tax expenses influencing net profit outcomes.

Operating Metrics

In assessing the operating metrics, Windlas Biotech Ltd's total expenses for Q4FY26 amounted to ₹222.69 crores, which signifies a QoQ rise of 2.3% from ₹217.70 crores in Q3FY26 and a YoY increase of 19.2% from ₹186.83 crores in Q4FY25. The tax expenses in Q4FY26 were ₹4.17 crores, showing a significant QoQ decrease of 16.1% from ₹4.97 crores in Q3FY26 and a YoY decrease of 8.1% from ₹4.54 crores in Q4FY25. These financial metrics reflect the company's operational spending and tax management over the respective periods, impacting the overall financial performance and net profitability.